Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer – guidance (TA705)

NICE recommend atezolizumab for untreated metastatic non-small-cell lung cancer in adults if: there is PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells, and there are no EGFR or ALK mutations.

Source:

National Institute for Health and Care Excellence